Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

ldx

  • Home
  •  
  • ldx



  • Most Read
  • Latest Comments
  • Lumos FDA appeal rejected yet again
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Lumos FDA appeal rejected yet again
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • Lumos FDA appeal rejected yet again
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • Lumos FDA appeal rejected yet again
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • Lumos FDA appeal rejected yet again
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • Lumos Diagnostics expands FebriDx distribution to Belgium
    Lumos Diagnostics expands FebriDx distribution to Belgium
    • News

  • Lumos completes phase 1 of developing premature birth detection test
    Lumos completes phase 1 of developing premature birth detection test
    • News

  • Lumos gets FDA approval for its bacteria detecting test, finally moves past its RAT test days
    Lumos gets FDA approval for its bacteria detecting test, finally moves past its RAT test days
    • News

  • Lumos FDA appeal rejected yet again
    Lumos FDA appeal rejected yet again
    • News

  • Lumos to stem the haemorrhaging by shutting down Florida manufacturing facility
    Lumos to stem the haemorrhaging by shutting down Florida manufacturing facility
    • News

  • Lumos FDA appeal rejected yet again
    • News

    Lumos FDA appeal rejected yet again

    One of the punching bags of the ASX, Lumos Diagnostics (ASX: LDX),  which develops diagnostics for healthcare professionals to more accurately diagnose and manage medical conditions, has announced the closure of its Sarasota manufacturing facility in Florida as they shift operations across the country to Carlsbad, California.  The decision to close one of its sites

    Read More
    Public
  • False positives: Lumos shares slaughtered as FDA knocks back application for viral infection test kits
    • News

    False positives: Lumos shares slaughtered as FDA knocks back application for viral infection test kits

    While small cap shareholders have become accustomed to major share price gains once a medtech or biotech receives FDA approval to commercialise their products, it’s not all sunshine and rainbows on the FDA horizon as Lumos Diagnostics (ASX: LDX) has found, following the rejection of their FebriDx test kits.  As a rapid diagnostic test that

    Read More
    Public
  • Lumos Diagnostics receives regulatory approval for rapid test in Brazil
    • News

    Lumos Diagnostics receives regulatory approval for rapid test in Brazil

    Rapid antigen tests (or lack thereof) have dominated the headlines for months now. Turning your kitchen counter into a mini pathology lab is now an essential ritual in determining if it’s the sniffles or the dreaded ‘c word’.  Specialists in rapid point-of-care diagnostic technologies, Lumos Diagnostics (ASX: LDX) have been working on a useful test,

    Read More
    Public
  • RATs – The ASX-listed companies manufacturing Rapid Antigen Tests that you cannot buy
    • News

    RATs – The ASX-listed companies manufacturing Rapid Antigen Tests that you cannot buy

    With ‘Rapid Antigen Test’ having only taken several days to likely be one of the most commonly used words of 2022, everyone is looking for them but demand is monumentally outweighing supply. With their surge in use, it may only be a matter of time until Australian regulators fast-track approval of more RAT manufacturers with

    Read More
    Public
  • Lumos receives first orders from Canada for rapid COVID test kits following regulatory approval
    • News

    Lumos receives first orders from Canada for rapid COVID test kits following regulatory approval

    Having secured approval from regulators in Canada last month, Lumos Diagnostics (ASX: LDX) is set to dispatch the first orders of their rapid antigen test kit to the Maple nation with the initial orders valued at USD $250,000 (AUD $350,000).  The orders are for Lumos’ CoviDx™ test kit which will enable qualified healthcare providers to

    Read More
    Public
  • IPO Watch: Lumos to accelerate decentralised healthcare diagnostics with $187m float
    • News

    IPO Watch: Lumos to accelerate decentralised healthcare diagnostics with $187m float

    With ever increasing bodies of medical research and demand for early disease detection climbing, it’s high time that we rethink diagnostic testing. The trend of having to wait three days to see if your pee is free of nasties is fraught with administration challenges and can delay treatment. Spend time in any medical establishment and

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.